Sector News

J&J, Actelion approach Swiss takeover board over deal structure: paper

January 9, 2017
Life sciences

Johnson & Johnson and Actelion have asked Switzerland’s takeover board about the viability of a complicated takeover deal the U.S. healthcare company is discussing with the Swiss biotech firm, newspaper Tages-Anzeiger reported on Friday, without saying how it got the information.

The two companies asked about the proposal under which Johnson & Johnson would acquire Actelion while separating its commercialized portfolio from its research and development assets, a deal structure first reported by Reuters last week.

The panel’s preliminary review was still going on, the paper said.

The Tages-Anzeiger quotes a spokesman for the takeover board as saying it does not comment on specific transactions. The Swiss takeover board, which determines whether a deal meets legal requirements, did not immediately respond to a request by Reuters for comment.

An Actelion spokesman also did not immediately respond to a request for comment.

The proposed deal structure would allow J&J to acquire Actelion with a cash offer in the region of $260 per share, a little more than what it had offered when it walked away from negotiations earlier in December.

It also would allow Actelion shareholders to benefit financially from Actelion’s R&D pipeline, people familiar with the matter told Reuters.

In return for a minority stake in the remaining business to develop new drugs, Johnson & Johnson could invest $1 billion to $2 billion over several years into Actelion’s research activities as part of the deal, the Tages-Anzeiger reported, again without saying where the information came from.

By Joshua Franklin

Source: Reuters

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.